🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› USA
Clinical trial register · United States · industry-sponsored

Industry-sponsored studies with a US investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9110 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:16 UTC
9110
Studies in scope
industry-sponsored, all four open statuses
4947
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
Florida 151 California 150 Arizona 97 Georgia 87 Illinois 72
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca299 Novartis Pharmaceuticals202 Eli Lilly and Company190 Merck Sharp & Dohme LLC183 AbbVie172 Clear sponsor filter
State
Florida151 California150 Arizona97 Georgia87 Illinois72
All 44 states
Target enrolment
to
190 of 9110 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Active, closed
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280Type 1 Diabetes, Obesity, Overweight
Eli Lilly and Company
Phase 3
465
California, Colorado, Florida, Iowa, Minnesota, Missouri, Nevada, North Carolina
2025-05-12
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
Eli Lilly and Company
Phase 3
905
California, Colorado, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa
2025-04-25
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475Type 2 Diabetes
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
700
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2025-03-27
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942Psoriasis, Overweight or Obesity
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Active, closed
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026Psoriatic Arthritis, Overweight or Obesity
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-03-06
Active, closed
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268Obesity
Eli Lilly and Company
Phase 3
643
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky
2025-03-05
Recruiting
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400Parkinson Disease
Eli Lilly and Company
Phase 1
127
California, Florida, Michigan, Texas, Washington
2025-02-18
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122Type 2 Diabetes
Eli Lilly and Company
Phase 3
55
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-01-10
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
Eli Lilly and Company
Phase 3
125
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-18
Recruiting
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939Obesity, Overweight
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Illinois, Louisiana, Missouri, North Carolina, Pennsylvania
2024-11-18
Active, closed
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383Obesity
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2024-11-01
Recruiting
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768Alzheimer Disease, Healthy
Eli Lilly and Company
Phase 1
128
California, Florida, Georgia, Michigan, New Jersey, North Carolina
2024-10-29
Active, closed
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706Glioma
Eli Lilly and Company
Phase 2
45
California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas
2024-10-25
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-10-24
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Active, closed
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728Obesity, Overweight
Eli Lilly and Company
Phase 2
252
Alabama, California, Florida, Hawaii, Illinois, Mississippi, Pennsylvania, Washington
2024-10-21
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic
Eli Lilly and Company
Phase 2
143
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2024-10-10
Recruiting
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
NCT06566170Alzheimer Disease
Eli Lilly and Company
Observational
6,250
Alabama
2024-10-07
Active, closed
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571Obesity, Overweight
Eli Lilly and Company
Phase 2
367
Arizona, California, Connecticut, Florida, Idaho, Illinois, Iowa, Kansas
2024-09-20
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Active, closed
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
NCT06606106Overweight, Obesity
Eli Lilly and Company
Phase 1
302
California, Florida, Missouri, Texas
2024-09-05
Recruiting
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590Alzheimer Disease
Eli Lilly and Company
Phase 1
48
Florida, Georgia, Massachusetts, New Jersey, North Carolina
2024-08-15
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Missouri
2024-07-01
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
Eli Lilly and Company
Phase 3
300
California, Delaware, Idaho, Illinois, Indiana, New York, Texas, Utah
2024-06-03
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 1
575
Arizona, California, Georgia, Michigan, New York, Ohio, Texas, Utah
2024-05-20
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Eli Lilly and Company
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-04-30
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eli Lilly and Company
Phase 3
510
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-04-29
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
Eli Lilly and Company
Phase 3
450
California, Colorado, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2024-04-26
Active, closed
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
NCT06220669Multiple Sclerosis
Eli Lilly and Company
Phase 2
63
Florida, Illinois, Missouri, South Carolina, Tennessee
2024-03-19
Active, closed
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603Type 2 Diabetes
Eli Lilly and Company
Phase 3
320
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Montana
2024-03-15
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
Eli Lilly and Company
Phase 3
90
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Eli Lilly and Company
Phase 3
17,300
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-03-05
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Florida, Georgia, Massachusetts, Missouri, New York, Texas
2024-03-05
Active, closed
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722Diabetes Mellitus, Type 2
Eli Lilly and Company
Phase 3
1,250
Alabama, California, Colorado, Florida, Georgia, Hawaii, Idaho, Indiana
2024-02-21
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-21
Recruiting
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956Obesity, Overweight
Eli Lilly and Company
Phase 2
1,481
Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa
2023-11-17
Active, closed
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667Obesity, Overweight
Eli Lilly and Company
Phase 3
160
Georgia, Idaho, Kansas, Louisiana, Maryland, Minnesota, Missouri, Ohio
2023-10-16
Active, closed
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252Type 2 Diabetes, Obesity
Eli Lilly and Company
Phase 2
414
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-09-21
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
Eli Lilly and Company
Phase 3
3,127
Arizona, California, Colorado, Florida, Georgia, Hawaii, Idaho, Kansas
2023-06-05
Recruiting
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139Breast Cancer, Solid Tumors, Adult
Eli Lilly and Company
Phase 1/2
880
California, Colorado, Connecticut, Florida, Georgia, Iowa, Louisiana, Massachusetts
2023-04-17
By invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483Atopic Dermatitis, Eczema
Eli Lilly and Company
Phase 3
333
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2023-03-09
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,175
Arizona, California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Rhode Island
2023-02-28
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
Eli Lilly and Company
Phase 3
595
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2023-02-27
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
Eli Lilly and Company
Phase 1
677
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2023-01-12
Active, closed
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359Atopic Dermatitis, Eczema
Eli Lilly and Company
Phase 3
377
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2022-10-18
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
Eli Lilly and Company
Phase 3
15,374
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2022-10-11
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-10-04
Active, closed
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
NCT05440786Sarcoma, Ewing, Neoplasm Metastasis
Eli Lilly and Company
Phase 2
46
Arizona, California, Indiana, Missouri, Rhode Island
2022-09-20
Active, closed
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584Type 2 Diabetes
Eli Lilly and Company
Phase 4
780
Alabama, California, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky
2022-08-01
Recruiting
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705Breast Cancer
Eli Lilly and Company
Phase 1
260
Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Missouri, New York
2022-05-11
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
Eli Lilly and Company
Phase 3
925
Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kentucky
2022-04-14
Active, closed
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567Breast Neoplasm, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
368
Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Illinois
2022-03-11
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
152
California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Tennessee, Texas
2021-12-20
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Arizona, California, Colorado, Florida, Hawaii, Illinois, Indiana, Kentucky
2021-10-04
Active, closed
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866Alzheimer Disease
Eli Lilly and Company
Phase 3
2,996
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-08-27
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
Eli Lilly and Company
Phase 1/2
540
Alabama, California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Hampshire
2021-07-19
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Massachusetts, Missouri, New York, Pennsylvania, Texas
2021-05-26
Active, closed
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326Chronic Migraine
Eli Lilly and Company
Phase 3
312
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2020-11-25
Active, closed
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Eli Lilly and Company
Phase 1
260
California, Florida, Illinois, Massachusetts, New York, North Carolina, Tennessee, Texas
2020-11-19
Active, closed
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
NCT04521686Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Eli Lilly and Company
Phase 1
200
Arizona, California, Florida, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2020-10-01
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
Eli Lilly and Company
Phase 3
996
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Indiana
2020-06-22
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511Alzheimer Disease
Eli Lilly and Company
Phase 3
1,736
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2020-06-19
Active, closed
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
NCT04106219Neuroblastoma
Eli Lilly and Company
Phase 1
71
California, Colorado, Illinois, Massachusetts, Ohio, Pennsylvania, Texas
2020-06-11
Recruiting
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
NCT05986292Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Eli Lilly and Company
Phase 2
10,000
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2020-01-30
Recruiting
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994Neoplasms, Child, Adolescent
Eli Lilly and Company
Phase 2
105
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2020-01-22
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
Eli Lilly and Company
Phase 1
379
Arizona, Arkansas, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2019-12-10
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
Eli Lilly and Company
Phase 1/2
36
California, Colorado, Florida, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2019-06-13
Active, closed
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365Prostate Cancer
Eli Lilly and Company
Phase 2/3
393
Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana, Massachusetts
2018-11-26
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
Eli Lilly and Company
Phase 3
1,058
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2018-07-18
Active, closed
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286Episodic Migraine
Eli Lilly and Company
Phase 3
533
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2018-03-14
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
Eli Lilly and Company
Phase 3
5,637
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2017-07-12
Active, closed
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Eli Lilly and Company
Phase 1/2
857
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana
2017-05-02
Active, closed
A Study of LY3200882 in Participants With Solid Tumors
NCT02937272Solid Tumor
Eli Lilly and Company
Phase 1
223
Kentucky, New York, Texas
2016-11-21
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779751Non Small Cell Lung Cancer, Breast Cancer
Eli Lilly and Company
Phase 1
100
Arkansas, California, Colorado, Massachusetts, Michigan, New York
2016-11-14
Active, closed
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
NCT02951598Alzheimer Disease, Mild Cognitive Impairment
Eli Lilly and Company
Observational
1,400
California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas, Kentucky
2016-10-29
Active, closed
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
NCT02747004Metastatic Breast Cancer
Eli Lilly and Company
Phase 2
234
Arizona, New Hampshire, Tennessee, Texas, Wisconsin
2016-09-14
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
Eli Lilly and Company
Phase 2
309
Arizona, California, District of Columbia, Florida, Michigan, Missouri, Pennsylvania, Tennessee
2016-05-19
Active, closed
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448Metastatic Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3
545
California, Colorado, Hawaii, Kansas, New York, North Carolina, Pennsylvania
2015-05-06
Active, closed
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621Breast Cancer
Eli Lilly and Company
Phase 3
493
Arizona, Arkansas, California, Florida, Georgia, Minnesota, Nebraska, Nevada
2014-11-06
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631Non Small Cell Lung Cancer
Eli Lilly and Company
Phase 3
453
Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois, Indiana
2014-10-03
Active, closed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703Breast Neoplasms
Eli Lilly and Company
Phase 3
669
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2014-07-22
Active, closed
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02057133Breast Neoplasms
Eli Lilly and Company
Phase 1
198
Arkansas, California, Massachusetts, Minnesota, New York, North Carolina, Oregon, Pennsylvania
2014-03-10
Active, closed
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
NCT01594723Neoplasms, Hematologic
Eli Lilly and Company
Phase 2
110
Arkansas, California, Connecticut, Florida, Illinois, Indiana, Kansas, Maryland
2012-05-22
By invitation
Zyprexa® Relprevv™ Patient Care Program
NCT01088386Schizophrenia
Eli Lilly and Company
Observational
4,000
Pennsylvania
2010-03-03
Rows per page Showing 101–190 of 190
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-usa?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.